CFO James E. Levine purchases 7,716 shares across 3 transactions at $4.76 blended average; cluster buy with 2 other insiders in past 14 days.
CFO James E. Levine executed 3 separate purchases totaling 7,716 shares for $36,725.50, increasing his holdings by 12.9% from 60,000 to 67,716 shares over three consecutive trading days (Dec 16-18, 2024). The timing spans a period when the stock moved from $3.83 to $5.42, and the company is currently trading at $4.49, down 24.0% from its 52-week high of $5.91 but up 74.0% over the past 30 days and 77.5% over 90 days. Cardiff Oncology remains unprofitable with a net income of $-11.9M despite 26.4% annual revenue growth, and concurrent purchases by 2 other insiders within the past 14 days indicate a cluster buy pattern. This coordinated insider accumulation at a stage when the stock has recently rebounded substantially merits attention to understand whether insiders perceive fundamental improvement or valuation opportunity.